Gilead’s New O’Day Regime Has New R&D Structure
Executive Summary
After several staff departures, Gilead consolidates its research arm under CEO oversight, while welcoming another Roche/Genentech alum.
You may also be interested in...
Gilead Writes Down Kite Buy As Yescarta Sales Flatten Out
Gilead takes $800m impairment charge against Kite acquisition a year after an $820m write-down. Kite and Yescarta are appear to be afterthoughts in discussions of Gilead’s portfolio and pipeline.
Gilead Says Sluggish Yescarta Business Will Continue To Fluctuate
The CAR-T therapy’s sales declined 2% from the previous quarter, although EU sales are growing briskly. The HIV franchise posted its best quarter ever, but the company’s overall financial performance was flat.
Gilead’s Descovy Nabs Limited HIV Prophylaxis Indication Pending A New Study In Women
US FDA approves a PrEP indication for emtricitabine/tenofovir alafenamide that excludes cisgender women due to a lack of efficacy evidence; Gilead will conduct a new randomized trial with a novel design in women comparing Descovy's efficacy and safety against external controls and Truvada.